Popular analogues
Ceftriaxone substitutes are included in the subgroup of cephalosporins; they contain the same active component. The selection of analogues is carried out by the attending physician, taking into account the causes of adverse reactions to therapy.
1. Lorakson
The medicine is indicated for the treatment of diseases caused by pathogenic microflora:
- peritonitis, meningitis, infections due to immune dysfunction;
- inflammation of the bronchi and lungs;
- tonsillitis, sinusitis, pharyngitis, sinusitis;
- cholecystitis, paraproctitis, pancreatitis.
The drug is suitable for the treatment of lesions of bone, joint, soft tissue and dermis. Loraxone is used to prevent secondary infections in the postoperative period.
2. Sulbactomax
The medication is used for infections:
- respiratory department;
- skin;
- urinary system;
- urogenital tract;
- bone and joint tissues.
Admission is approved for patients with immunodeficiencies and cancer - to prevent secondary infectious processes. The drug is prescribed in the preoperative and postoperative period.
Pharmacodynamics and pharmacokinetics
A combined product, the main components of which are: sulbactam (beta-lactamase inhibitor) and ampicillin (semi-synthetic penicillin antibiotic).
The drug has a wide range of antimicrobial effects and is acid-resistant.
The principle of action is based on blocking the synthesis of petidoglycan, located in the cell wall of bacteria.
The main effect is exerted by the antibiotic ampicillin, which is destroyed by beta-lactamases.
Sulbactam (the second component of the drug Sultasin) allows you to inhibit the action of beta-lactamases, which makes ampicillin stable and more effective.
The antibiotic affects gram-positive flora, enterobacteria, neisseria, streptococci , peptococci, Proteus, Klebsiella, clostridia , enterobacteria, Escherichia coli, and grim-negative microorganisms.
Sultasin does not affect Pseudomonas aeruginosa , penicillinase-producing staphylococci.
Expensive substitutes
The list of good, but high-cost products includes Azaran and Rocephin. The drugs are recommended for the treatment of minors due to rare cases of side effects, manifested by:
- breathing problems, cough;
- obsessive itching, dermatological rash, red spots;
- nettle fever, serum sickness, anaphylaxis.
During therapy there are no unpleasant sensations in the gastrointestinal tract or changes in the composition of the blood.
Indications for use
The antibiotic Sultasin is prescribed for bacterial infections of various localizations caused by microorganisms sensitive to the action of ampicillin.
Respiratory system: chronic bronchitis, lung abscess , pneumonia, pleural empyema. ENT organs: otitis media, tonsillitis, sinusitis.
Genitourinary system: endometritis, cystitis, pyelitis, pyelonephritis , prostatitis, urethritis .
Soft tissues and skin: dermatitis (secondarily infected), impetigo , erysipelas.
Biliary tract: development of cholangitis, formation of cholecystitis or exacerbation of a chronic process.
Gastrointestinal tract: salmonella carriage, salmonellosis , dysentery.
The drug is prescribed for peritonitis, infectious lesions of the osteoarticular system, gonococcal infection, scarlet fever, septic endocarditis , for the prevention of postoperative complications after surgical interventions on the pelvic organs and abdominal cavity.
Injection analogues
Popular substitutes for Ceftriaxone in the form of injections are presented:
- Cefazolin - used to combat infections of the skin and soft tissues, and prevent postoperative complications. For adults, 1-2 g is prescribed up to three times a day, for children - from 50 to 80 mg per kilogram of weight, for 2-3 daily procedures.
- Cefuroxime is a drug used for the treatment of community-acquired pneumonia, diseases of the genitourinary tract, and in surgical practice. The medication is prescribed in a dosage of 2.25 to 4.5 g three times a day, for children - from 50 to 100 mg per kilogram of weight, up to 4 times a day.
- Cefotaxime is a strong antibiotic that suppresses the activity of streptococcal infections. The drug is approved for newborns and is prescribed for meningitis and hospital-acquired infectious pathologies. Dosed at 3-4 g up to four doses per day, for children - from 50 to 100 mg per kilogram of weight, up to 6 procedures daily.
- Ceftazidime – fights Pseudomonas aeruginosa, is used for low white blood cell levels. The medicine is not used for streptococci, 3-6 g is prescribed up to 3 procedures per day, for children - from 3 to 100 mg/kg, the drug is administered after 6 hours.
- Cefoperazone - may cause adverse reactions such as bleeding. The active components are excreted through the liver and do not penetrate into the brain tissue well. Adults are recommended to take 4-12 g of medication, divided into 4 procedures, children - from 50 to 100 mg/kg, the total amount is divided into 3 procedures.
- Cefepime is a fourth-generation antibiotic that suppresses the activity of pathogens resistant to certain cephalosporins. It is used for patients with a weakened body, with a complex course of infectious processes provoked by several types of bacteria. Adults are prescribed 2 to 4 g twice a day, children - 50 mg/kg, three times a day.
The above dosages are intended for daily injections. The total amount is divided into several doses, observing the intervals between injections recommended by the instructions.
Sultasin powder for i/v/im/m 1g+500mg fl 1 pc
Pharmacological group:
Antibiotic, semi-synthetic penicillin + beta-lactamase inhibitor.
Pharmacodynamics:
Sultasin is a broad-spectrum bactericidal antibiotic, acid-resistant. Blocks the synthesis of peptidoglycan in the cell wall of microorganisms. The active ingredient is ampicillin, a semi-synthetic broad-spectrum antibiotic that is destroyed by beta-lactamases. The second component (sulbactam), without having antibacterial activity (with the exception of Neisseriaceae and Acinetobacter), inhibits beta-lactamases and, therefore, ampicillin acquires the ability to act on resistant (beta-lactamase-producing) strains. Active against gram-positive aerobes: Staphylococcus aureus (beta-lactamase-producing and non-producing strains), Staphylococcus epidermidis (beta-lactamase producing and non-producing strains), Staphylococcus saprophyticus (beta-lactamase producing and non-producing strains), Enterococcus faecalis, Streptococcus pneumoniae (including including strains resistant to penicillin), Streptococcus pyogenes, Streptococcus spp. viridans groups, Listeria monocytogenes; gram-negative aerobes: Hemophilus influenzae (including strains resistant to ampicillin), Moraxella catarrhalis (beta-lactamase producing and non-producing strains), Escherichia coli, Klebsiella spp., Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Morganella morganii, Neisseria gonorrhoeae (beta-lactamase-producing and non-beta-lactamase-producing strains); anaerobes: Clostridium spp. (except Clostridium difficile), Peptococcus spp., Peptostreotococcus spp., Bacteroides spp., including Bacteroides fragilis. Resistant: methicillin-resistant Staphylococcus spp., most strains of Enterobacter spp., Cirobacter spp., Pseudomohas aeruginosa, Mycobacterium spp., Clostridium difficile, Chlamydia spp. and mycoplasma.
Pharmacokinetics:
Penetrates into most tissues and body fluids; During inflammation, permeability into the cerebrospinal fluid increases sharply. After IV and IM administration, high concentrations of sulbactam and ampicillin in the blood are achieved. T1/2 - 1 hour (for ampicillin and sulbactam). Excreted by the kidneys - 70-80%, mainly unchanged, as well as with bile and breast milk. Sulbactam undergoes almost no metabolic transformations and is excreted by the kidneys mainly unchanged and only about 25% in the form of metabolites.
Side effects
Hemostasis system, hematopoietic organs: decreased number of platelets, leukocytes, severe anemia.
pseudomembranous enterocolitis rarely develops during treatment with Sultasin , vomiting, nausea and increased liver enzymes are noted.
Nervous system: headaches, mild malaise, increased drowsiness.
Allergic responses: conjunctivitis, rhinitis, angioedema, urticaria, anaphylactic shock, eosinophilia, fever, skin hyperemia, arthralgia, anaphylactic shock .
When administering the drug intramuscularly, there is mild pain in the injection area; phlebitis rarely develops .
Long-term therapy can lead to the development of candidiasis and superinfection.
Interaction
The antibiotic is incompatible with aminoglycosides , protein hydrolysates, and blood products.
Food, laxatives, glucosamine , antacids, aminoglycosides can reduce the quality and rate of absorption ; the opposite effect is observed when taking ascorbic acid.
A synergistic effect is observed with respect to rifampicin, vancomycin, cycloserine , cephalosporins, aminoglycosides and other bactericidal antibiotics.
An antagonistic effect is observed against chloramphenicol , macrolides, sulfonamides, tetracyclines, lincosamides and other bacteriostatic drugs.
Sultasin reduces the prothrombin index , the synthesis of vitamin K, suppresses intestinal microflora, increases the effectiveness of indirect anticoagulants , the opposite effect is observed when taking oral contraceptives and other medications, during the metabolism of which PABA is formed.
NSAIDs, phenylbutazone, allopurinol, diuretics increase the level of antibiotic in the blood.
The risk of skin rash increases with concomitant therapy with allopurinol.
Sultasin's analogs
Level 4 ATX code matches:
Arlet
Ecoclave
Panclave
Amoxiclav
Oxamp-Sodium
Oxamp
Amoxicillin + Clavulanic acid
Augmentin
Ampisid
Amoxil K 625
Flemoklav Solutab
Analogues of the drug Sultasin: Unazin , Sulbacin , Ampisid and Sulacillin .
special instructions
Course therapy must be carried out under the monitoring of performance indicators of the hepatic system, kidneys, and hematopoietic organs.
In patients suffering from hypersensitivity to penicillins, cross-allergic reactions to cephalosporins are observed.
Superinfection can develop due to the growth of insensitive microflora; in this case, a replacement of the antibacterial drug is required.
The Jarisch-Herxheimer reaction (bacteriolysis) can develop when treating patients with sepsis.
